Multiple sclerosis: early management.
The management of multiple sclerosis (MS) is changing, and for the first time treatments which appear to influence the course of the disease are becoming available. This article examines our current understanding of MS pathogenesis and assesses which, if any, of the emerging therapies are likely to make an impact on this potentially disabling condition.
Zajicek
J
J
Department of Neurology, Derriford Hospital, Plymouth.
D000305:Adrenal Cortex Hormones / Q000627:therapeutic use; D003711:Demyelinating Diseases / Q000628:therapy; D006801:Humans; D007262:Infusions, Intravenous; D016899:Interferon-beta / Q000627:therapeutic use; D008775:Methylprednisolone / Q000627:therapeutic use; D009103:Multiple Sclerosis / Q000209:etiology* / Q000628:therapy; D010919:Placebos; D016032:Randomized Controlled Trials as Topic
D000305:Adrenal Cortex Hormones; D010919:Placebos; D016899:Interferon-beta; D008775:Methylprednisolone